Recent Developments in Treatment of Latent Tuberculosis Infection
Author Information
Author(s): Dick Menzies, Hamdan Al Jahdali, Badriah Al Otaibi
Primary Institution: Montreal Chest Institute, McGill University, Montreal, Quebec, Canada
Hypothesis
Can shorter regimens for treating latent tuberculosis infection (LTBI) be as effective as the standard 6-12 month isoniazid therapy?
Conclusion
Latent tuberculosis infection therapy is underutilized, especially in low and middle-income countries, despite its effectiveness in preventing active TB.
Supporting Evidence
- More than 80% of individuals with active TB are contagious and can transmit the infection.
- INH therapy can reduce the risk of developing active TB by 25% to 92% in individuals with LTBI.
- Shorter treatment regimens have been developed to improve patient compliance and reduce adverse effects.
Takeaway
This study looks at how to treat people who have a sleeping form of tuberculosis so they don't get sick later. It finds that shorter treatments might work just as well as longer ones.
Methodology
The article reviews evidence from systematic reviews and randomized trials regarding the efficacy, completion, and adverse effects of various LTBI treatment regimens.
Potential Biases
Potential biases include underreporting of adverse events and variability in treatment adherence across different settings.
Limitations
The study highlights that completion rates for LTBI therapy are often below 50%, particularly in low and middle-income countries.
Participant Demographics
The study references trials involving diverse populations, including those with HIV and varying socioeconomic backgrounds.
Want to read the original?
Access the complete publication on the publisher's website